- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT04786457
ADVP005; Dengue CVD 12000 - Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC)
27. října 2021 aktualizováno: Kirsten Lyke, University of Maryland, Baltimore
A Phase 1, Open-Label Clinical Trial With Dengue-1-Virus Live Virus Human Challenge (DENV-1-LVHC) Assessment of Healthy U.S. Adults Previously Primed With Tetravalent Dengue Virus Purified Inactivated Vaccine (TDEN-PIV) and Boosted With Tetravalent Dengue Virus Live Attenuated Vaccine Formulation (TDEN LAV)
The purpose of this research study is to test the protection of volunteers previously vaccinated with Tetravalent Dengue Virus (TDEN) Purified Inactivated Vaccine (PIV) with alum and boosted with TDEN live attenuated vaccine (LAV) formulation against a weakened form of an experimental dengue virus challenge.
The Investigators will also include people that have not received the study vaccine.
The Investigators are collecting information about how the vaccine protects against a dengue virus challenge as well as adding to knowledge about the safety of the challenge.
Přehled studie
Postavení
Dokončeno
Podmínky
Intervence / Léčba
Detailní popis
The purpose of this research study is to test the protection of volunteers previously vaccinated with Tetravalent Dengue Virus (TDEN) Purified Inactivated Vaccine (PIV) with alum and boosted with TDEN live attenuated vaccine (LAV) formulation against a weakened form of an experimental dengue virus challenge.
The Investigators will also include people that have not received the study vaccine.
The Investigators are collecting information about how the vaccine protects against a dengue virus challenge as well as adding to knowledge about the safety of the challenge.
The information will help Investigators develop vaccines to protect people from dengue.
Participation is voluntary.
The duration of participation will last for 180 days (six months).
After participants are exposed to the weakened dengue virus, the Investigators will follow them closely to measure their symptoms.
Like the flu, participants might expect to have a headache, rash, body aches, fever and chills or they may experience no symptoms whatsoever.
If a participant does develops symptoms, the Investigators will monitor him/her closely in a local hotel or a wing of our hospital to ensure safety and to treat symptoms if they occur.
Participants will be compensated for their time.
Typ studie
Intervenční
Zápis (Aktuální)
17
Fáze
- Fáze 1
Kontakty a umístění
Tato část poskytuje kontaktní údaje pro ty, kteří studii provádějí, a informace o tom, kde se tato studie provádí.
Studijní místa
-
-
Maryland
-
Baltimore, Maryland, Spojené státy, 21201
- University of Maryland, Baltimore, Center for Vaccine Development and Global Health
-
-
Kritéria účasti
Výzkumníci hledají lidi, kteří odpovídají určitému popisu, kterému se říká kritéria způsobilosti. Některé příklady těchto kritérií jsou celkový zdravotní stav osoby nebo předchozí léčba.
Kritéria způsobilosti
Věk způsobilý ke studiu
18 let až 50 let (Dospělý)
Přijímá zdravé dobrovolníky
Ano
Pohlaví způsobilá ke studiu
Všechno
Popis
Inclusion Criteria:
- 1. Male or non-pregnant, non-breastfeeding female between 18 and 50 years of age (inclusive) at the time of consent.
- 2. Tetravalent dengue antibody response at 28 days following final vaccination for vaccinated groups of volunteers.
- 3. Volunteers must be able and willing to provide written informed consent.
- 4. Volunteers must be healthy as established by medical history and clinical examination at study entry.
- 5. Volunteers must pass a comprehension test and be able to comply with all study requirements.
- 6. Female volunteers of non-childbearing potential (non-childbearing potential is defined as having had one of the following: a tubal ligation at least 3 months prior to enrollment, a hysterectomy, an oophorectomy, or is post-menopausal).
- 7. Female volunteers of childbearing potential may be enrolled in the study, if all of the following apply:
- Practiced adequate contraception (see Definition of Terms, section 5.4.2.3.) for 30 days prior to challenge
- Has a negative urine pregnancy test on the day of DHIM
- Agrees to continue adequate contraception until two months after completion of the DHIM
- 8. Provide consent for release of medical history records from primary care physician, college or university medical center, urgent care, or emergency room visit
Exclusion Criteria:
- 1. Planned travel during the study period (180 days) which would interfere with the ability to complete all study visits
- 2. Recent (in the past 4 weeks) travel to any dengue endemic area. These potential volunteers may be eligible for enrollment a minimum of 4 weeks later
- 3. Volunteer seropositive for hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (anti-HCV), or human immunodeficiency virus antibodies (anti-HIV)
- 4. Unvaccinated volunteers positive for antibodies to flaviviruses (FV) to include dengue virus, West Nile virus, Yellow Fever virus, Zika virus, and Japanese encephalitis virus.
- 5. Any history of FV infection or FV vaccination except for participation in the ADVP003 or ADVP004 dengue vaccination studies; during the study period (Note: Late time point serology from the trials can be tested concomitant to screening serology to clarify if incident FV infection has occurred between vaccination and challenge)
- 6. Medical history of, or current, diabetes, chronic obstructive pulmonary disease, peptic ulcer disease, coronary artery disease, cardiac arrhythmia, cardiomyopathy, pericarditis, or auto-immune disease
- 7. Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)
- 8. History of Guillain-Barré syndrome (GBS)
- 9. History of bipolar disorder, schizophrenia, hospitalization in the past year for a mental health disorder, or any other psychiatric condition, which in the opinion of the investigator prevents the volunteer from participating in the study
- 10. Safety laboratory test results at screening that are deemed clinically significant or more than Grade 1 deviation from normal with the exception of PT/PTT, fibrinogen decrease, ALT/AST increase (<1.1 x ULN acceptable), platelet decrease which will be exclusionary at Grade 1 or higher
- 11. Significant screening physical examination abnormalities at the discretion of the investigator, including a BMI > 35 kg/m2
- 12. Women who intend to become pregnant or men who intend to father a child during the study period (approximately 6 months)
- 13. Female: pregnant, lactating or history of heavy menstrual bleeding menstrual periods lasting consistently and regularly longer than 6 days, or consistently and regularly requiring 5 or more pads or tampons per day, and volunteer to the opinion and review of the investigator.
- 14. Female volunteers using an intrauterine device (IUD) or Mirena®
- 15. Female volunteers with a history of clinically significant fibroids or uterine polyps, endometriosis, dysmenorrhea, adenomyosis, and uterine scarring (e.g. after D&C), unless treated, with no active clinically significant disease
- 16. Allergy (hives, shortness of breath, swelling of the lips or throat), or hospitalization related to a previous vaccination, anaphylaxis of unknown etiology, or allergy to specific medications/animals for which antigens may be in the virus preparations to include: Shellfish allergy, Fetal Bovine Serum, L-Glutamine, Neomycin and Streptomycin
- 17. Recent blood donation within prior 56 days of inoculation or planning to donate blood in the one 1 year following inoculation with dengue virus
- 18. Receipt of blood products or antibodies within 90 days of inoculation or during the study period
- 19. Any personal beliefs that bar the administration of blood products, transfusions, or serum albumin
- 20. Participation in the 4 weeks preceding inoculation, or planned participation during the present trial period, in another clinical trial investigating a vaccine except for participation in the ADVP003 or ADVP004 study, drug, medical device, or medical procedure
- 21. Planned administration of a licensed or study vaccine not planned in the study protocol during the period starting 30 days prior to the DHIM for a live vaccine or 14 days prior to DHIM for inactivated vaccines and extending until 56 days after study completion
- 22. Planned or current administration of an HMG-CoA reductase inhibitor (i.e., lovastatin, simvastatin, atorvastatin, etc.)
- 23. Currently taking methadone or suboxone
- 24. Currently regularly taking anti-coagulant medication, aspirin or non-steroidal anti-inflammatory drugs (NSAIDs)
- 25. Chronic migraine headaches, defined as more than 15 headache days per month over a 3-month period of which more than 8 are migraines, in the absence of medication over use
- 26. Chronic or recent acute medical condition that, in the opinion of the investigator, impacts volunteer safety.
Studijní plán
Tato část poskytuje podrobnosti o studijním plánu, včetně toho, jak je studie navržena a co studie měří.
Jak je studie koncipována?
Detaily designu
- Primární účel: Základní věda
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
---|---|
Experimentální: Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)
open-label injection of DENV-1-LVHC to 15-20 adults who were previously vaccinated and 5 adults who have never received a dengue vaccination
|
one subcutaneous injection of Dengue 1 Live Virus Human Challenge (DENV-1-LVHC) at 0.5 mL of 6.5 x 10^3 PFU/mL
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
---|---|---|
Výskyt abnormálních laboratorních měření
Časové okno: přibližně šest měsíců
|
Výskyt abnormálních laboratorních měření do 28 dnů po inokulaci viru nebo 7 dnů po hospitalizaci, podle toho, co nastane později
|
přibližně šest měsíců
|
Solicited Injection Site Adverse Events
Časové okno: approximately six months
|
solicited injection site adverse event until 7 days post virus inoculation
|
approximately six months
|
Unsolicited Injection Site Adverse Events
Časové okno: approximately six months
|
unsolicited injection site adverse events until 28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
approximately six months
|
Solicited Systemic Adverse Events
Časové okno: approximately six months
|
solicited systemic adverse events until 28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
approximately six months
|
Dengue-Related Adverse Events
Časové okno: approximately six months
|
dengue-related like adverse events until 28 days post virus inoculation or 7 days post inpatient whichever is later
|
approximately six months
|
Unsolicited Systemic Adverse Events
Časové okno: approximately six months
|
unsolicited systemic adverse events until 28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
approximately six months
|
Short-Term SAEs
Časové okno: approximately six months
|
Number of SAEs until 28 days post virus inoculation or 7 days post hospitalization, whichever is later
|
approximately six months
|
Long-Term SAEs
Časové okno: approximately seven months
|
Number of SAEs until 6 months post virus inoculation
|
approximately seven months
|
Fever
Časové okno: approximately seven months
|
The occurrence of fever defined as greater than or equal to 38°C (100.4°
F) measured at least 2 times at least 4 hours apart
|
approximately seven months
|
Spolupracovníci a vyšetřovatelé
Zde najdete lidi a organizace zapojené do této studie.
Termíny studijních záznamů
Tato data sledují průběh záznamů studie a předkládání souhrnných výsledků na ClinicalTrials.gov. Záznamy ze studií a hlášené výsledky jsou před zveřejněním na veřejné webové stránce přezkoumány Národní lékařskou knihovnou (NLM), aby se ujistily, že splňují specifické standardy kontroly kvality.
Hlavní termíny studia
Začátek studia (Aktuální)
30. listopadu 2020
Primární dokončení (Aktuální)
9. července 2021
Dokončení studie (Aktuální)
9. července 2021
Termíny zápisu do studia
První předloženo
24. listopadu 2020
První předloženo, které splnilo kritéria kontroly kvality
3. března 2021
První zveřejněno (Aktuální)
8. března 2021
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
28. října 2021
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
27. října 2021
Naposledy ověřeno
1. října 2021
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
Další identifikační čísla studie
- HP-00088798
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Ano
Studuje produkt zařízení regulovaný americkým úřadem FDA
Ne
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Dengue 1 Live Virus Human Challenge (DENV-1-LVHC)
-
State University of New York - Upstate Medical...Walter Reed Army Institute of Research (WRAIR); U.S. Army Medical Research...Aktivní, ne nábor